{"id":"NCT02280044","sponsor":"Johns Hopkins Bloomberg School of Public Health","briefTitle":"Efficacy of Rifaximin in Preventing Campylobacteriosis","officialTitle":"Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-10","primaryCompletion":"2016-08-09","completion":"2016-08-09","firstPosted":"2014-10-31","resultsPosted":"2018-11-20","lastUpdate":"2018-11-20"},"enrollment":30,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Dysentery","Diarrhea","Enteric Campylobacteriosis"],"interventions":[{"type":"BIOLOGICAL","name":"Rifaximin intervention","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo intervention","otherNames":[]}],"arms":[{"label":"rifaximin","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is a randomized, double-blinded, placebo-controlled, in-patient trial evaluating the prophylactic efficacy of rifaximin against campylobacteriosis following challenge with C. jejuni.","primaryOutcome":{"measure":"Campylobacteriosis","timeFrame":"120 hours after challenge","effectByArm":[{"arm":"Rifaximin","deltaMin":13,"sd":null},{"arm":"Placebo","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["23840001","22864805","20086085","19842970","18809665","21896097","20412178","12809830","15017618","21050319","17382603","11692292","29145631"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["Abdominal Cramps","Chills","Headache","Malaise","anorexia"]}}